Xeris Biopharma Holdings, Inc.
General ticker "XERS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $810.4M (TTM average)
Xeris Biopharma Holdings, Inc. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 2.3%: low 6.61$, high 6.92$
Factors to consider:
- Total employees count: 394 (+4.5%) as of 2024
- Top business risk factors: Product development risks, Operational and conduct risks, Market volatility, Regulatory and compliance, Product liability
- Current price 23.6% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.44$, 5.44$]
- 2025-12-31 to 2026-12-31 estimated range: [2.27$, 5.11$]
Financial Metrics affecting the XERS estimates:
- Positive: with PPE of -10.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.38 <= 0.33
- Positive: Inventory ratio change, % of 0.02 <= 0.84
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 0.97 > -0.66
- Negative: negative Industry operating cash flow (median)
Short-term XERS quotes
Long-term XERS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $110.25MM | $163.91MM | $203.07MM |
| Operating Expenses | $192.19MM | $207.92MM | $236.72MM |
| Operating Income | $-81.94MM | $-44.01MM | $-33.65MM |
| Non-Operating Income | $-14.14MM | $-19.49MM | $-23.46MM |
| Interest Expense | $14.10MM | $26.61MM | $33.17MM |
| R&D Expense | $20.97MM | $22.34MM | $25.56MM |
| Income(Loss) | $-96.08MM | $-63.50MM | $-57.10MM |
| Taxes | $-1.42MM | $-1.25MM | $-2.27MM |
| Profit(Loss)* | $-94.66MM | $-62.26MM | $-54.84MM |
| Stockholders Equity | $45.19MM | $-6.78MM | $-29.61MM |
| Inventory | $24.73MM | $38.84MM | $48.17MM |
| Assets | $344.52MM | $322.60MM | $323.06MM |
| Operating Cash Flow | $-102.89MM | $-47.02MM | $-36.98MM |
| Capital expenditure | $0.52MM | $2.26MM | $0.87MM |
| Investing Cash Flow | $34.46MM | $-6.00MM | $4.88MM |
| Financing Cash Flow | $127.47MM | $-1.61MM | $36.17MM |
| Earnings Per Share** | $-0.70 | $-0.45 | $-0.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.